Please assess the completion status of the following clinical trial:

Trial Title: Autologous Cell Therapy for Treatment of Fecal Incontinence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary symptoms of fecal incontinence, as confirmed by patient medical history and physical examination~* Wexner (Cleveland Clinic Incontinence Severity (CCIS)) score ≥ 9~* Etiology of fecal incontinence is related, at least in part, to external anal sphincter dysfunction~* Failed conservative treatment~Exclusion Criteria:~* Gracilis sling repair or insertion of an artificial sphincter~* Inflammatory Bowel Disease~* Significant rectocele or rectal prolapse~* History of radiation treatment to the anal sphincter or adjacent structures~* Less than 18 years of age~* Pregnant, breastfeeding, or plans to become pregnant during the course of the study~* Neuromuscular disorder~* History of neoplasia within 5 years prior to enrollment, except for basal cell carcinoma, or is receiving or planning to receive anti-cancer medications~* Known bleeding diathesis or uncorrected coagulopathy~* Medical condition that would preclude treatment due to contraindications and/or warnings of concomitant medications or listed in the experimental product labeling~* Compromised immune system due to disease state, chronic corticosteroid use, or other immunosuppressive therapy~* Participating in another investigational drug or device study~* Unable or unwilling to provide informed consent~* Unable or unwilling to commit to the follow-up procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iltamiocel (Type: EXPERIMENTAL): AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intrasphincteric injection of 250 x 10\^6 cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).